Zimmer Biomet (ZBH) Q4 2025 Earnings Transcript

Motley Fool Transcribing, The Motley Fool

Tue, February 10, 2026 astatine 9:07 AM CST 48 min read

Image source: The Motley Fool.

Tuesday, Feb. 10, 2026 astatine 8:30 a.m. ET

• Chief Executive Officer — Ivan Tornos

• Executive Vice President & Chief Financial Officer — Suketu Upadhyay

• Vice President, Investor Relations — David DeMartino

Ivan Tornos: Good morning, everyone, and convey you for joining today's call. I would similar to commencement the mode that I ever do, by sharing my gratitude to our Zimmer Biomet squad members astir the satellite who determination our concern and ngo guardant each and each day. Thank you for your tireless work. Thank you for your dedication to solving the astir pressing challenges successful wellness care. And convey you for your relentless committedness to serving our customers and their patients. Today, Zimmer Biomet is simply a wholly antithetic institution than it was conscionable a fewer abbreviated years ago, and this is nary uncertainty owed to your efforts. During my prepared remarks this morning, I'll screen 4 cardinal areas.

I'll commencement by summarizing our 4th fourth results and the results for the fiscal twelvemonth 2025. Second, I'll supply an update connected the program which we are executing upon to germinate our U.S. Commercial organization. Thirdly, I'll present our 2026 guidance. Lastly, I'll concisely screen the advancement that we person made crossed our cardinal strategical priorities, those being radical and culture, operational excellence, and thirdly, innovation and diversification. Starting with the twelvemonth and the 4th quarter, I'm arrogant of however the squad ended the twelvemonth 2025, delivering connected our commitments connected income growth, EPS, and escaped currency travel portion navigating rather a analyzable situation successful the year. Tariff headwinds, and integrating 3 acquisitions wrong 1 year.

From a changeless currency integrated gross standpoint, we ended 2025 close astatine the mediate of our archetypal yearly guidance, marking the 5th consecutive twelvemonth for Zimmer Biomet increasing mid-single digit oregon above. Looking astatine the 4th fourth results, we grew income connected an integrated changeless currency ground by 5.4% against a mid-single digit maturation comparable with our captious U.S. Business expanding 5.7% and planetary increasing 5%. Healthy extremity markets, caller merchandise momentum, the ongoing improvement of our U.S. Sales channel, and the caller enactment additions proceed to thrust an acceleration successful our captious U.S. Business. U.S.

Knee maturation of 6% successful the 4th was driven by accrued penetration of Persona OsteoTide orthogoxalamus knee, which ended the twelvemonth astir astir 35% penetration. Our Oxford partial cementless genu continues to present supra expectations with adoption rates post-training continued to beryllium precise precocious with large conversions from competitory accounts. Notably, our DTP, Direct to Patient Awareness Campaign, successful concern with Arnold Schwarzenegger, drove accelerated momentum successful the 2nd fractional of the twelvemonth with a personalized genu run yielding precise meaningful results.